It was reported yesterday that the US Food and Drug Administration (USFDA) has granted breakthrough therapy designation to United States-based Celgene's Pomalyst (pomalidomide) intended for the treatment of HIV.
The designation has been granted for the product to treat patients with HIV-positive Kaposi sarcoma who have earlier received systemic chemotherapy, in addition to patients with HIV-negative Kaposi's sarcoma.
Pomalyst is one of the firm's IMiD agents for the treatment of some blood cancers. It is a thalidomide analogue indicated, in combination with dexamethasone, to treat patients with multiple myeloma who have received at least two prior therapies including lenalidomide and proteasome inhibitor.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval